Advertisement

AHRQ Series Commentary 3: The United States addresses comparative effectiveness but not cost-effectiveness through the Effective Health-Care Program

      In this issue of the journal, authors from the Effective Health-Care Program of the Agency for Healthcare Research & Quality (AHRQ) outline their approach for appraising research evidence and providing “… understandable and actionable information for patients, clinicians, and policy makers” [
      • Slutsky J.
      • Atkins D.
      • Chang S.
      • Sharp B.A.C.
      AHRQ Series Paper 1: Comparing medical interventions: AHRQ and the Effective Health-Care Program.
      ]. The methods outlined are not controversial, and it is clear that the program of work is of a high standard. However, in matters of health technology appraisal, the devil is often in the detail or at least in the implementation, and it is interesting to observe controversy emerging when vested interests are challenged.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Clinical Epidemiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Slutsky J.
        • Atkins D.
        • Chang S.
        • Sharp B.A.C.
        AHRQ Series Paper 1: Comparing medical interventions: AHRQ and the Effective Health-Care Program.
        J Clin Epidemiol. 2010; 63 (In this issue): 481-483
        • Freemantle N.
        Does the UK need a fourth hurdle for pharmaceutical reimbursement to encourage the more cost effective prescribing of pharmaceuticals?.
        Health Policy. 1999; 46: 255-265
        • Freemantle N.
        • Henry D.
        • Maynard A.
        • Torrance G.
        Promoting cost-effective prescribing: Great Britain lags behind.
        BMJ. 1995; 310: 955-956
        • Sheldon T.A.
        • Cullum N.
        • Dawson D.
        • Lankshear A.
        • Lowson K.
        • Watt I.
        • et al.
        What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes, and interviews.
        BMJ. 2004; 329: 999-1004
        • Freemantle N.
        Is NICE delivering the goods?.
        BMJ. 2004; 329: 1003-1004
        • Orszag P.R.
        Research on the comparative effectiveness of medical treatments: options for an expanded federal role. CBO Testimony, Subcommittee on Health, Committee on Ways and Means, US House of Representatives.
        Congressional Budget Office, Washington, DC2007
        • Wilensky G.R.
        Cost-effectiveness information: yes, it's important, but keep it separate, please!.
        Ann Intern Med. 2008; 148: 967-968